RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
for Adenocarcinoma of Lung
Drug: Durvalumab
10 locations incl. Phoenix
Sponsor: Masonic Cancer Center, University of Minnesota
Sex: All·Age: 18+
Code: NCT04105270·Phase 2·Recruiting